<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2019.1012075</article-id><article-id pub-id-type="publisher-id">JCT-96853</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  The Effect of Body Mass Index on Survival in Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aiat</surname><given-names>Morsy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samir</surname><given-names>Shehata</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>12</issue><fpage>883</fpage><lpage>894</lpage><history><date date-type="received"><day>9,</day>	<month>June</month>	<year>2019</year></date><date date-type="rev-recd"><day>30,</day>	<month>November</month>	<year>2019</year>	</date><date date-type="accepted"><day>3,</day>	<month>December</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background
  <b>:</b>
  <b> </b>
  Obesity is a well-known risk factor for breast cancer recurrence and poor prognosis. The objective of this study was to evaluate the effect of body mass index (BMI) on survival in breast cancer patients.
   
  <b>Methods</b>
  <b>: </b>
  We performed a retrospective analysis of 50 breast cancer patients treated in our hospital from January 2012 to December 2013. Patients were divided according to body mass index when diagnosed into: normal weight BMI &lt;
   
  25 Kg/m<sup>2</sup>, over weight BMI 
  ≥ 25 Kg/m<sup>2</sup> to &lt; 30 Kg/m<sup>2</sup>, obesity BMI ≥
   
  30 Kg/m<sup>2</sup>. In this study the effect of body mass index on progression free survival (PFS) and overall survival (OS) was evaluated.
   
  <b>Results</b>
  <b>: </b>
  The disease free survival (DFS) and overall survival (OS) decreased in overweight and obese patients. Both overweight and obesity were predictors for increased risks of breast cancer relapse and mortality with a median disease free survival for overweight 29 mons and obese patients 11 mons and a median overall survival for overweight patients 49 mons and obese patients 39 mons.
   
  <b>Conclusion</b>
  <b>: </b>
  Obesity and overweight are associated with poorer disease free survival and overall survival in patients with breast cancer.
 
</p></abstract><kwd-group><kwd>Body Mass Index</kwd><kwd> Breast Cancer</kwd><kwd> Obesity</kwd><kwd> Overweight</kwd><kwd> Relapse</kwd><kwd> Mortality</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Obesity or overweight has become an emerging health concern worldwide with over 500 million adults were obese and 958 million were overweight in 2008, [<xref ref-type="bibr" rid="scirp.96853-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref2">2</xref>] and overweight or obesity was also reported to be a risk factor for increased incidence of various forms of cancer [<xref ref-type="bibr" rid="scirp.96853-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref4">4</xref>]. Breast cancer is the most common malignant neoplasm among women [<xref ref-type="bibr" rid="scirp.96853-ref5">5</xref>] and being overweight or obese in adults is associated with a greater risk of breast cancer. [<xref ref-type="bibr" rid="scirp.96853-ref6">6</xref>]. Also nowadays there is widespread consensus on the importance of obesity or overweight as a negative prognostic factor for breast cancer [<xref ref-type="bibr" rid="scirp.96853-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref8">8</xref>].</p><p>In 2004, Berclaz et al. [<xref ref-type="bibr" rid="scirp.96853-ref9">9</xref>] have reported that obesity or overweight is associated with a poor prognosis after breast cancer treatment, and other studies also suggested that obesity at the time of cancer diagnosis or pre-diagnosis is associated with poor prognosis for breast cancer patients [<xref ref-type="bibr" rid="scirp.96853-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref11">11</xref>]. In addition, it has been shown that breast cancer patients with higher body mass index (BMI) estimated as obesity or overweight have a worse prognosis disease regardless of tumor subtype [<xref ref-type="bibr" rid="scirp.96853-ref12">12</xref>].</p><p>A review of 26 studies involved 29,460 women and showed that increased BMI was associated with adverse prognosis of breast cancer [<xref ref-type="bibr" rid="scirp.96853-ref13">13</xref>]. In a meta-analysis, it was reported that in patients with increased BMI, the risk of recurrence was 1.91 (95% CI, 1.52 - 2.40) at 5 years and the risk of death was 1.6 (95% CI, 1.38 - 1.76) at 10 years. These results showed that obese women have an increased risk of recurrence and death. In a prospective cohort study including 512 women with early-stage breast cancer (T1 - T3, N0 - N1, and M0), increased BMI was strongly associated with poor DFS and OS [<xref ref-type="bibr" rid="scirp.96853-ref14">14</xref>]. In many large cohort studies inverse association between increased BMI and breast cancer mortality was evident [<xref ref-type="bibr" rid="scirp.96853-ref15">15</xref>]. The adverse effect of obesity on breast cancer prognosis was detected both in pre and postmenopausal women [<xref ref-type="bibr" rid="scirp.96853-ref15">15</xref>]. However, there were controversial results regarding the association of obesity and survival in premenopausal women. In many studies there was inverse association between breast cancer risk and premenopausal women [<xref ref-type="bibr" rid="scirp.96853-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref17">17</xref>].</p><p>Several mechanisms are suggested to explain the association between obesity and poor prognosis of breast cancer. The most widely discussed mechanisms are the effect of obesity on the hormonal status of women and tumor characteristics. However, up till now no study showed an exact underlying pathophysiological mechanism [<xref ref-type="bibr" rid="scirp.96853-ref15">15</xref>].</p><p>Therefore, in this study, we aimed to assess the effect of BMI on recurrence pattern and survival in breast cancer patients.</p></sec><sec id="s2"><title>2. Patients and Methods</title><sec id="s2_1"><title>2.1. Patient Characteristics</title><p>This retrospective study analyzed the data of 50 breast cancer patients who were admitted at the department of clinical oncology, Assiut university hospital from January 2012 to December 2013. Patients who had body mass index values were included in the study. The patients who had metastatic disease at the time of diagnosis were excluded from the study. Body mass index was calculated as weight (Kg)/height 2 (m<sup>2</sup>) and patients were classified into three categories: normal body weight BMI &lt; 25 Kg/m<sup>2</sup>, overweight BMI ≥ 25 to &lt; 30 Kg/m<sup>2</sup> and obesity BMI ≥ 30 Kg/m<sup>2</sup>.</p><p>Information of patients was obtained covering age, height, weight, menopausal status, history of contraception, pathology, grade, clinical stage, lymph vascular invasion, ER, PR, HER 2 and treatment (surgery, chemotherapy, radiotherapy and endocrine therapy).</p><p>All study participants provided written informed consent and the study protocol and procedures were approved by the ethics committee in our faculty.</p></sec><sec id="s2_2"><title>2.2. Follow up</title><p>Follow-up has been maintained by reviewing clinical charts and by contacting patients via telephone. Events used for the analysis were mortality of breast cancer or relapse including local, regional and contralateral breast cancer or distant breast cancer recurrence. Survival status was censored at the date of last contact or 31 December 2018 (last follow-up). DFS defined as the time of diagnosis to development of first evidence of recurrence (distant metastasis or local regional recurrence) or date of the last follow-up. OS was defined as from the time of diagnosis to last follow-up or time of mortality.</p></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>In our study, the associations between different BMI groups and clinic pathologic characteristics of breast cancer patients were analyzed by the chi-square test. Data were analyzed with the help of SPSS version 23 software, which included descriptive analysis. Mean was calculated for quantitative variables. Disease free survival and overall survival were calculated (Tables 1-12 and Figures 1-4).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >1-Age 2-Weight 3-Height 4-BMI 5-BMI status: &#183; Normal &#183; Overweight &#183; Obesity 6-Menopausal status: &#183; Pre-menopausal &#183; Post-menopausal 7-History of contraceptive: &#183; No &#183; Yes</td><td align="center" valign="middle" >49.72 &#177; 10.88 77.54 &#177; 18.16 1.55 &#177; 0.05 31.97 &#177; 7.02 6 (12.0%) 18 (36.0%) 26 (52.0%) 25 (50.0%) 25 (50.0%) 24 (48.0%) 26 (52.0%)</td></tr></tbody></table></table-wrap><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical data</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >1-Pathology: &#183; DCIS &#183; IDC &#183; ILC</td><td align="center" valign="middle" >1 (2.0%) 46 (92.0%) 3 (6.0%)</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >2-Grade: &#183; 1 &#183; 2 &#183; 3 3-N1: &#183; 0 &#183; 1 - 5 &#183; 5 - 10 &#183; &gt;10 4-N2: &#183; 0 &#183; 1 - 5 &#183; 5 - 10 &#183; &gt;10 6-Clinical stage: &#183; I &#183; IA &#183; IIA &#183; IIB &#183; IIIA &#183; IIIB &#183; IIIC &#183; IV 7-Lymphovascular invasion: &#183; No &#183; Yes 8-ER: &#183; −ve &#183; +ve 9-PR: &#183; −ve &#183; +ve 10-HER-2: &#183; −ve &#183; +ve</th><th align="center" valign="middle" >1 (2.0%) 39 (78.0%) 10 (20.0%) 14 (28.0%) 18 (36.0%) 11 (22.0%) 7 (14.0%) 5 (10.0%) 10 (20.0%) 30 (60.0%) 5 (10.0%) 2 (4.0%) 1 (2.0%) 14 (28.0%) 8 (16.0%) 10 (20.0%) 2 (4.0%) 9 (18.0%) 4 (8.0%) 32 (64.0%) 18 (36.0%) 25 (50.0%) 25 (50.0%) 27 (54.0%) 23 (46.0%) 11 (22.0%) 10 (20.0%)</th></tr></thead></tbody></table></table-wrap></table-wrap-group><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Surgery data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >Surgery: &#183; Breast conservative surgery (BCS) &#183; Modified radical mastectomy (MRM)</td><td align="center" valign="middle" >20 (40%) 30 (60%)</td></tr></tbody></table></table-wrap><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Radical local &amp; palliative radiotherapy &amp; hormonal therapy data</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >Radical local radiotherapy: &#183; No &#183; Yes Palliative radiotherapy: &#183; No &#183; Yes Hormonal therapy-Tamoxifen (Tam): &#183; No &#183; Yes</td><td align="center" valign="middle" >16 (32.0%) 34 (68.0%) 34 (68.0%) 16 (32.0%) 30 (60.0%) 20 (40.0%)</td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle" >Duration of Tam Hormonal therapy-Aromatase inhibitors (AI): &#183; No &#183; Yes Duration of AI Herceptin: &#183; Yes &#183; No</th><th align="center" valign="middle" >2.78 &#177; 1.85 31 (62.0%) 19 (38.0%) 2.87 &#177; 1.54 1 (2.0%) 49 (98.0%)</th></tr></thead></tbody></table></table-wrap></table-wrap-group><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Toxicity data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >Toxicity: &#183; No &#183; Acute bronchitis &#183; Cardio toxicity &#183; Fungal infection &#183; Neutropenia &#183; Pancytopenia</td><td align="center" valign="middle" >45 (90.0%) 1 (2.0%) 1 (2.0%) 1 (2.0%) 1 (2.0%) 1 (2.0%)</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Response data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >Response: &#183; Complete remission &#183; Partial remission</td><td align="center" valign="middle" >45 (90.0%) 5 (10.0%)</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Recurrence &amp; Metastasis data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Descriptive</th></tr></thead><tr><td align="center" valign="middle" >Recurrence: &#183; Local recurrence &#183; No recurrence Metastasis: &#183; Yes &#183; No</td><td align="center" valign="middle" >11 (22.0%) 39 (78.0%) 26 (52.0%) 24 (48.0%)</td></tr></tbody></table></table-wrap><table-wrap-group id="8"><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Relation between BMI and other variables</title></caption><table-wrap id="8_1"><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >BMI &lt; 25 “n = 6”</th><th align="center" valign="middle" >25 ≤ BMI &lt;30 “n = 18”</th><th align="center" valign="middle" >BMI ≥ 30 “n = 26”</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >1-Age at diagnosis: &#183; ≤36 yrs. &#183; 36 - 65 yrs. &#183; ≥65 yrs. 2-Menopausal: &#183; Premenopausal &#183; Postmenopausal 3-Lymph node metastases: &#183; 0 &#183; 1 - 3 &#183; ≥4</td><td align="center" valign="middle" >0 4 (66.7%) 2 (33.3%) 1 (16.7%) 5 (83.3%) 3 (50.0%) 1 (16.67%) 2 (33.3%)</td><td align="center" valign="middle" >4 (22.2%) 14 (77.8%) 0 11 (61.1%) 7 (38.9%) 7 (38.89%) 5 (27.78%) 6 (33.33%)</td><td align="center" valign="middle" >2 (7.7%) 22 (84.6%) 2 (7.7%) 13 (50.0%) 13 (50.0%) 6 (23.07%) 7 (26.9%) 13 (50.0%)</td><td align="center" valign="middle" >P &lt; 0.03 P &lt; 0.04 P &lt; 0.001</td></tr></tbody></table></table-wrap><table-wrap id="8_2"><table><tbody><thead><tr><th align="center" valign="middle" >4-Clinical stage: &#183; I &#183; IA &#183; IIA &#183; IIB &#183; IIIA &#183; IIIB &#183; IIIC &#183; IV 5-Lymphovascular invasion: &#183; No &#183; Yes 6-ER: &#183; −ve &#183; +ve 7-PR: &#183; −ve &#183; +ve 8-HER-2: &#183; −ve &#183; +ve 9-Toxicity: &#183; No &#183; Acute bronchitis &#183; Cardio toxicity &#183; Fungal infection &#183; Neutropenia &#183; Pancytopenia</th><th align="center" valign="middle" >1 (16.7%) 0 1 (16.7%) 0 2 (33.3%) 1 (16.7%) 1 (16.7%) 0 3 (50.0%) 3 (50.0%) 4 (66.7%) 2 (33.3%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 1 (16.7%) 6 (100%) 0 0 0 0 0</th><th align="center" valign="middle" >0 0 5 (27.8%) 2 (11.1%) 7 (38.9%) 0 2 (11.1%) 2 (11.1%) 11 (61.1%) 7 (38.9%) 11 (61.1%) 7 (38.9%) 12 (66.7%) 6 (33.3%) 3 (16.7%) 2 (11.1%) 16 (100%) 0 0 0 1 (5.5%) 1 (5.5%)</th><th align="center" valign="middle" >2 (7.7%) 1 (3.8%) 8 (30.8%) 6 (23.1%) 1 (3.8%) 1 (3.9%) 6 (23.1%) 2 (7.7%) 18 (69.2%) 8 (30.8%) 10 (38.5%) 16 (61.5%) 11 (42.3%) 15 (57.7%) 6 (23.1%) 7 (26.9%) 23 (88.5%) 1 (3.8%) 1 (3.8%) 1 (3.8%) 0 0</th><th align="center" valign="middle" >P = 0.365 n.s P = 0.643 n.s P = 0.230 n.s P = 0.225 n.s P = 0.375 n.s P &lt; 0.03</th></tr></thead></tbody></table></table-wrap></table-wrap-group><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Relation between Overall survival and BMI</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >BMI &lt; 25 “n = 6”</th><th align="center" valign="middle" >25 ≤ BMI &lt;30 “n = 18”</th><th align="center" valign="middle" >BMI ≥ 30 “n = 26”</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Mean &#177; SE Median</td><td align="center" valign="middle" >58.16 &#177; 3.67 58</td><td align="center" valign="middle" >49.50 &#177; 4.73 49</td><td align="center" valign="middle" >39.83 &#177; 10.24 39</td><td align="center" valign="middle" >P &lt; 0.001</td></tr></tbody></table></table-wrap><table-wrap id="table10" ><label><xref ref-type="table" rid="table1">Table 1</xref>0</label><caption><title> Relation between Progression free survival (PFS) and BMI</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >BMI &lt; 25 “n = 6”</th><th align="center" valign="middle" >25≤ BMI &lt;30 “n = 18”</th><th align="center" valign="middle" >BMI ≥ 30 “n = 26”</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Mean &#177; SE Median</td><td align="center" valign="middle" >42.27 &#177; 6.12 38</td><td align="center" valign="middle" >38.76 &#177; 5.32 29</td><td align="center" valign="middle" >28.16 &#177; 10.30 11</td><td align="center" valign="middle" >P &lt; 0.01</td></tr></tbody></table></table-wrap><table-wrap-group id="11"><label><xref ref-type="table" rid="table1">Table 1</xref>1</label><caption><title> Means and medians for survival time</title></caption><table-wrap id="11_1"><table><tbody><thead><tr><th align="center" valign="middle"  colspan="4"  >Mean<sup>a</sup></th><th align="center" valign="middle"  colspan="4"  >Median</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Estimate</td><td align="center" valign="middle"  rowspan="2"  >Std. error</td><td align="center" valign="middle"  colspan="2"  >95% confidence interval</td><td align="center" valign="middle"  rowspan="2"  >Estimate</td><td align="center" valign="middle"  rowspan="2"  >Std. error</td><td align="center" valign="middle"  colspan="2"  >95% confidence interval</td></tr><tr><td align="center" valign="middle" >Lower bound</td><td align="center" valign="middle" >Upper bound</td><td align="center" valign="middle" >Lower bound</td><td align="center" valign="middle" >Upper bound</td></tr><tr><td align="center" valign="middle" >38.760</td><td align="center" valign="middle" >3.724</td><td align="center" valign="middle" >31.462</td><td align="center" valign="middle" >46.058</td><td align="center" valign="middle" >35.000</td><td align="center" valign="middle" >7.071</td><td align="center" valign="middle" >21.141</td><td align="center" valign="middle" >48.859</td></tr></tbody></table></table-wrap><table-wrap id="11_2"><table><tbody><thead><tr><th align="center" valign="middle"  colspan="4"  >Mean<sup>a</sup></th><th align="center" valign="middle"  colspan="4"  >Median</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Estimate</td><td align="center" valign="middle"  rowspan="2"  >Std. error</td><td align="center" valign="middle"  colspan="2"  >95% confidence interval</td><td align="center" valign="middle"  rowspan="2"  >Estimate</td><td align="center" valign="middle"  rowspan="2"  >Std. error</td><td align="center" valign="middle"  colspan="2"  >95% confidence interval</td></tr><tr><td align="center" valign="middle" >Lower bound</td><td align="center" valign="middle" >Upper bound</td><td align="center" valign="middle" >Lower bound</td><td align="center" valign="middle" >Upper bound</td></tr><tr><td align="center" valign="middle" >51.460</td><td align="center" valign="middle" >3.101</td><td align="center" valign="middle" >45.382</td><td align="center" valign="middle" >57.538</td><td align="center" valign="middle" >59.000</td><td align="center" valign="middle" >4.710</td><td align="center" valign="middle" >49.768</td><td align="center" valign="middle" >68.232</td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap id="table12" ><label><xref ref-type="table" rid="table1">Table 1</xref>2</label><caption><title> Relation between PFS &amp; OS and BMI in premenopausal and postmenopausal patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >BMI &lt; 25 “n = 1”</th><th align="center" valign="middle" >25 ≤ BMI &lt;30 “n = 11”</th><th align="center" valign="middle" >BMI ≥ 30 “n = 13”</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >PFS premenopausal PFS postmenopausal OS premenopausal OS postmenopausal</td><td align="center" valign="middle" >41.90 &#177; 0.00 42.85 &#177; 18.50 57.27 &#177; 0.00 56.71 &#177; 13.31</td><td align="center" valign="middle" >37.30 &#177; 12.48 40.23 &#177; 16.64 46.69 &#177; 13.27 50.46 &#177; 13.94</td><td align="center" valign="middle" >35.21 &#177; 8.48 26.80 &#177; 12.50 40.25 &#177; 15.48 39.80 &#177; 18.31</td><td align="center" valign="middle" >P &lt; 0.03 P &lt; 0.01 P &lt; 0.04 P &lt; 0.03</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3"><title>3. Discussion</title><p>Obesity and overweight in adults have been reported to be associated with a greater risk of breast cancer, [<xref ref-type="bibr" rid="scirp.96853-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref17">17</xref>] while the studies that evaluated influence of overweight and obesity on breast cancer survival have shown mixed findings [<xref ref-type="bibr" rid="scirp.96853-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref19">19</xref>]. In an effort to address this gap, we conducted a retrospective study to make the relationship between obesity and breast cancer prognosis clear.</p><p>We also found that overweight and obesity were independent predictors for increased risks of breast cancer recurrence and death for the whole cohort. In a previous study from America, after 5-year follow-up, the authors calculated that hazard ratios (HR) for risks of relapse was 1.18 (95% CI 1.02 - 1.36) in overweight patients and breast cancer death was 1.23 (95% CI 1.00 - 1.52) in the obese group relative to the normal weight, while overweight did not affect recurrence and obesity wasn’t a predictor for breast cancer mortality [<xref ref-type="bibr" rid="scirp.96853-ref18">18</xref>]. In a study including African patients, overweight was significantly related to breast cancer death (HR 2.903, 95% CI: 1.551 - 5.432) and relapse (HR 1.899, 95% CI: 1.05 - 3.433) by multivariable analysis [<xref ref-type="bibr" rid="scirp.96853-ref20">20</xref>]. Another study found that the risks of developing distant metastasis were significantly increased for Danish obese patients, while both obesity and overweight women had a higher risk of breast cancer death relative to normal-weight women [<xref ref-type="bibr" rid="scirp.96853-ref21">21</xref>]. However, Kawai et al. reported that obesity was an independent risk factor for breast cancer mortality (HR: 1.47; 95% CI: 1.11 - 1.93) but not for relapse, and overweight had no association with breast cancer prognosis [<xref ref-type="bibr" rid="scirp.96853-ref22">22</xref>]. Nevertheless, in another study from America, Kwan et al. in 2012 [<xref ref-type="bibr" rid="scirp.96853-ref23">23</xref>] observed that overweight or obesity was not associated with increased risk of relapse and breast cancer death compared to normal weight, a report from the Korean Breast Cancer Society demonstrated similar results [<xref ref-type="bibr" rid="scirp.96853-ref19">19</xref>].</p><p>Although the association between obesity/overweight and the prognosis of breast cancer patients remains controversial, it has been reported that impact of BMI on prognosis of breast cancer may relate to menopausal status [<xref ref-type="bibr" rid="scirp.96853-ref24">24</xref>].</p><p>In a stratified analysis, it was found that being overweight was associated with increased risks of breast cancer recurrence and death within 5 years after breast cancer diagnosis for postmenopausal but not for premenopausal women, and obesity was an independently poor predictor for breast cancer recurrence and death regardless to menopausal status [<xref ref-type="bibr" rid="scirp.96853-ref25">25</xref>]. Similar to the study, Reeves et al. in 2007 have reported that obesity and overweight were related to increased breast cancer progression and mortality primarily in British postmenopausal women. A meta-analysis of 82 studies that included 213,075 breast cancer patients demonstrated that obesity was associated with higher risk of breast cancer mortality (HR, 1.41; 95% CI, 1.29 - 1.53) in both premenopausal (HR, 1.75; 95% CI, 1.26 - 2.41) and postmenopausal (HR, 1.34; 95% CI, 1.18 - 1.53) women [<xref ref-type="bibr" rid="scirp.96853-ref26">26</xref>], similar results were found by Niraula et al. in 2012 [<xref ref-type="bibr" rid="scirp.96853-ref27">27</xref>]. A study from Japan found that obesity and overweight were associated with a nonsignificant higher risk of relapse and breast cancer mortality for premenopausal women, and obesity but not overweight was associated with a significantly higher risk of breast cancer mortality for postmenopausal women (not for relapse) [<xref ref-type="bibr" rid="scirp.96853-ref22">22</xref>], results from a cohort study also suggest that obesity (not overweight) was an independent poor prognostic predictor for American postmenopausal breast cancer patients [<xref ref-type="bibr" rid="scirp.96853-ref28">28</xref>]. However, some authors [<xref ref-type="bibr" rid="scirp.96853-ref9">9</xref>] found that overweight or obesity is significantly associated with a shorter OS and DFS for premenopausal and perimenopause patients. Besides, another study including American breast cancer patients also demonstrated that overweight or obesity was positively associated with recurrence in premenopausal rather than postmenopausal women [<xref ref-type="bibr" rid="scirp.96853-ref24">24</xref>]. Moreover, some studies indicated that overweight is an independent prognostic factor for increased breast cancer death and relapse in premenopausal triple-negative breast cancer women, while similar results were not found in postmenopausal women [<xref ref-type="bibr" rid="scirp.96853-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.96853-ref29">29</xref>].</p><p>Our study found that overweight and obesity at diagnosis were related to poor prognosis of breast cancer irrespective of menopausal status, with worse progression free survival and overall survival in both pre and postmenopausal patients. The limitation of our study was the small sample size.</p></sec><sec id="s4"><title>4. Conclusion</title><p>Our study shows that both overweight and obesity are associated with poorer DFS and OS in breast cancer patients. However, further studies with a larger sample size and more comprehensive design are urgently warranted.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s6"><title>Cite this paper</title><p>Morsy, A. and Shehata, S. (2019) The Effect of Body Mass Index on Survival in Breast Cancer. Journal of Cancer Therapy, 10, 883-894. https://doi.org/10.4236/jct.2019.1012075</p></sec></body><back><ref-list><title>References</title><ref id="scirp.96853-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Finucane, M.M., Stevens, G.A., Cowan, M.J., et al. (2011) National, Regional, and Global Trends in Body-Mass Index Since 1980: Systematic Analysis of Health Examination Surveys and Epidemiological Studies with 960 Country-Years and 9.1 Million Participants. The Lancet, 377, 557-567. 
https://doi.org/10.1016/S0140-6736(10)62037-5</mixed-citation></ref><ref id="scirp.96853-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, T., Yang, W., Chen, C.S., et al. (2008) Global Burden of Obesity in 2005 and Projections to 2030. International Journal of Obesity, 32, 1431-1437. 
https://doi.org/10.1038/ijo.2008.102</mixed-citation></ref><ref id="scirp.96853-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Yang, D.L., Chen, Z.Z. and Gou, B.-F. (2016) Associations of Body Mass Index with Cancer Incidence among Populations, Genders, and Menopausal Status: A Systematic Review and Meta-Analysis. Cancer Epidemiology, 42, 1-8. 
https://doi.org/10.1016/j.canep.2016.02.010</mixed-citation></ref><ref id="scirp.96853-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Reeves, G.K., Pirie, K., Beral, V., et al. (2007) Cancer Incidence and Mortality in Relation to Body Mass Index in the Million Women Study: Cohort Study. British Medical Journal, 335, 1134. https://doi.org/10.1136/bmj.39367.495995.AE</mixed-citation></ref><ref id="scirp.96853-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254</mixed-citation></ref><ref id="scirp.96853-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Neuhouser, M.L., Aragaki, A.K., Prentice, R.L., et al. (2015) Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncology, 1, 611-621. https://doi.org/10.1001/jamaoncol.2015.1546</mixed-citation></ref><ref id="scirp.96853-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Protani, M., Coory, M. and Martin, J.H. (2010) Effect of Obesity on Survival of Women with Breast Cancer: Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment, 123, 627-635. https://doi.org/10.1007/s10549-010-0990-0</mixed-citation></ref><ref id="scirp.96853-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gevorgyan, A., Bregni, G., Galli, G., et al. (2016) Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. Tumori Journal, 102, e11-e14. https://doi.org/10.5301/tj.5000515</mixed-citation></ref><ref id="scirp.96853-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Berclaz, G., Li, S., Price, K.N., et al. (2004) Body Mass Index as a Prognostic Feature in Operable Breast Cancer: The International Breast Cancer Study Group Experience. Annals of Oncology, 15, 875-884. https://doi.org/10.1093/annonc/mdh222</mixed-citation></ref><ref id="scirp.96853-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Caan, B.J., Kwan, M.L., Hartzell, G., et al. (2008) Pre-Diagnosis Body Mass Index, Post-Diagnosis Weight Change, and Prognosis among Women with Early Stage Breast Cancer. Cancer Causes &amp; Control, 19, 1319-1328. 
https://doi.org/10.1007/s10552-008-9203-0</mixed-citation></ref><ref id="scirp.96853-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bao, P.P., Cai, H., Peng, P., et al. (2016) Body Mass Index and Weight Change in Relation to Triple-Negative Breast Cancer Survival. Cancer Causes &amp; Control, 27, 229-236. https://doi.org/10.1007/s10552-015-0700-7</mixed-citation></ref><ref id="scirp.96853-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Calle, E.E., Rodriguez, C., Walker-Thurmond, K., et al. (2003) Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. The New England Journal of Medicine, 348, 1625-1638.  
https://doi.org/10.1056/NEJMoa021423</mixed-citation></ref><ref id="scirp.96853-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chlebowski, R.T., Aiello, E. and McTiernan, A. (2002) Weight Loss in Breast Cancer Patient Management. Journal of Clinical Oncology, 20, 1128-1143. 
https://doi.org/10.1200/JCO.2002.20.4.1128</mixed-citation></ref><ref id="scirp.96853-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Goodwin, P.J., Ennis, M., Pritchard, K.I., et al. (2002) Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 20, 42-51. https://doi.org/10.1200/JCO.2002.20.1.42</mixed-citation></ref><ref id="scirp.96853-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yazici, O., Aksoy, S., Sendur, M.A., Babacan, T., Ozdemir, N., Ozisik, Y., Zengin, N. and Altundag, K. (2015) The Effect of Obesity on Recurrence Pattern in Early Breast Cancer Patients. Journal of BUON, 20, 954-962.</mixed-citation></ref><ref id="scirp.96853-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Renehan, A.G., Tyson, M., Egger, M., Heller, R.F. and Zwahlen, M. (2008) Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies. The Lancet, 371, 569-578. 
https://doi.org/10.1016/S0140-6736(08)60269-X</mixed-citation></ref><ref id="scirp.96853-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cheraghi, Z., Poorolajal, J., Hashem, T., Esmailnasab, N. and DoostiIrani, A. (2012) Effect of Body Mass Index on Breast Cancer during Premenopausal and Postmenopausal Periods: A Meta-Analysis. PLoS ONE, 7, e51446. 
https://doi.org/10.1371/journal.pone.0051446</mixed-citation></ref><ref id="scirp.96853-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Jiralerspong, S., Kim, E.S., Dong, W., et al. (2013) Obesity, Diabetes, and Survival Outcomes in a Large Cohort of Early-Stage Breast Cancer Patients. Annals of Oncology, 24, 2506-2514. https://doi.org/10.1093/annonc/mdt224</mixed-citation></ref><ref id="scirp.96853-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Moon, H.G., Han, W. and Noh, D.Y. (2009) Underweight and Breast Cancer Recurrence and Death: A Report from the Korean Breast Cancer Society. Journal of Clinical Oncology, 27, 5899-5905. https://doi.org/10.1200/JCO.2009.22.4436</mixed-citation></ref><ref id="scirp.96853-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Al Jarroudi, O., Abda, N., Seddik, Y., et al. (2017) Overweight: Is It a Prognostic Factor in Women with Triple-Negative Breast Cancer? Asian Pacific Journal of Cancer Prevention, 18, 1519-1523.</mixed-citation></ref><ref id="scirp.96853-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ewertz, M., Jensen, M.B., Gunnarsdottir, K.A., et al. (2011) Effect of Obesity on Prognosis after Early-Stage Breast Cancer. Journal of Clinical Oncology, 29, 25-31. 
https://doi.org/10.1200/JCO.2010.29.7614</mixed-citation></ref><ref id="scirp.96853-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kawai, M., Tomotaki, A., Miyata, H., et al. (2016) Body Mass Index and Survival after Diagnosis of Invasive Breast Cancer: A Study Based on the Japanese National Clinical Database—Breast Cancer Registry. Cancer Medicine, 5, 1328-1340. 
https://doi.org/10.1002/cam4.678</mixed-citation></ref><ref id="scirp.96853-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kwan, M.L., Chen, W.Y., Kroenke, C.H., et al. (2012) Pre-Diagnosis Body Mass Index and Survival after Breast Cancer in the after Breast Cancer Pooling Project. Breast Cancer Research and Treatment, 132, 729-739.  
https://doi.org/10.1007/s10549-011-1914-3</mixed-citation></ref><ref id="scirp.96853-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Warren, L.E., Ligibel, J.A., Chen, Y.H., et al. (2016) Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. Annals of Surgical Oncology, 23, 3870-3879. https://doi.org/10.1245/s10434-016-5437-3</mixed-citation></ref><ref id="scirp.96853-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Sun, L., Zhu, Y., Qian, Q. and Tang, L. (2018) Body Mass Index and Prognosis of Breast Cancer: An Analysis by Menstruation Status When Breast Cancer Diagnosis. Medicine, 97, e11220. https://doi.org/10.1097/MD.0000000000011220</mixed-citation></ref><ref id="scirp.96853-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chan, D.S., Vieira, A.R., Aune, D., et al. (2014) Body Mass Index and Survival in Women with Breast Cancer-Systematic Literature Review and Meta-Analysis of 82 Follow-up Studies. Annals of Oncology, 25, 1901-1914.  
https://doi.org/10.1093/annonc/mdu042</mixed-citation></ref><ref id="scirp.96853-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Niraula, S., Ocana, A., Ennis, M. and Goodwin, P.J. (2012) Body Size and Breast Cancer Prognosis in Relation to Hormone Receptor and Menopausal Status: A Meta-Analysis. Breast Cancer Research and Treatment, 134, 769-781.  
https://doi.org/10.1007/s10549-012-2073-x</mixed-citation></ref><ref id="scirp.96853-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Conroy, S.M., Maskarinec, G., Wilkens, L.R., et al. (2011) Obesity and Breast Cancer Survival in Ethnically Diverse Postmenopausal Women: The Multiethnic Cohort Study. Breast Cancer Research and Treatment, 129, 565-574. 
https://doi.org/10.1007/s10549-011-1468-4</mixed-citation></ref><ref id="scirp.96853-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Hao, S., Liu, Y., Yu, K.D., et al. (2015) Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. PLoS ONE, 10, e0129741. 
https://doi.org/10.1371/journal.pone.0129741</mixed-citation></ref></ref-list></back></article>